Statistical Issues in the Study & Design of Cardiovascular Disease
February 10, 2016
11:00am-5pm, Yawkey Conference Center, DFCI
RSVP to mplante@hsph.harvard.edu
This half-day symposium, sponsored by the Harvard Catalyst Biostatistics Program, will focus on many aspects of the study of cardiovascular disease. Sessions will discuss biomarkers and risk prediction, genetics studies, clinical trials, observational studies, and post-marketing safety studies. Each session will feature a talk by a clinician-scientist, who will introduce the context and major issues in design and analysis, which will then be followed by talks by statisticians, who will present new methods and approaches to design and analysis. Each session will include time for questions and discussion. Lunch will be provided.
Session 1: Biomarkers and risk prediction and stratification
· Novel assays for cardiac troponin: diagnosis, risk prediction, and treatment
Brendan Everett, MD, MPH, Director, General Cardiology Inpatient Service, Brigham & Women’s Hospital
· Guidelines for cardivoscular therapy: risk- or benefit-based?
Nancy Cook, ScD, Professor, Division of Preventive Medicine, Brigham and Women’s Hospital, Harvard Medical School
Session 2: Genetics studies
· Identifying novel genes for blood pressure
Dan Levy, MD, Professor of Medicine, Boston University School of Medicine, Chief, Population Sciences Branch of the National Heart, Lung, and Blood Institute, Director, Framingham Heart Study
· Mega-genetic analysis applied to studies of human longevity and cardiovascular free survival
Paola Sebastiani, PhD, Professor of Biostatistics & Bioinformatics, Boston University
Session 3: Clinical trials
· Clinical Outcome Trials are not either positive or negative
Marc Pfeffer, MD, PhD, Professor of Medicine, Harvard Medical School
· Experiences with interim trial monitoring, and misunderstanding about early stopped trials
Robert Glynn, ScD, Professor of Biostatistics, Harvard T.H. Chan School of Public Health
· Moving beyond the comfort zone in practicing translational statistics for clinical studies
LJ Wei, PhD, Professor of Biostatistics, Harvard T.H. Chan School of Public Health
Session 4: Observational studies
· Design and analytical issues in the family-based Framingham Study
Vasan Ramachandran, MD, DM, Cardiovascular epidemiologist, Framingham Heart Study
· Assessing the effect of sleep disturbances on blood pressure adjusting for the use of hypertension medication
Rui Wang, PhD, Assistant Professor of Medicine, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women’s Hospital
· Methodologies for the Study of Precipitants of Acute Cardiovascular Events
Murray Mittleman, MPH, DrPH, Professor of Epidemiology, Harvard T.H. Chan School of Public Health
Session 5: Post-marketing safety studies
· FDA’s Sentinel System for assessing the safety of marketed medical products
Richard Platt, MD, MSc, Professor and Chair, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute
· An overview of Sentinel’s current analytic capability and unmet needs
Lingling Li, PhD, Associate Professor & Biostatistician, Department of Population Medicine, Harvard Medical School, Director, Biostatistics Center, Harvard Medical School
With opening remarks by Rebecca Betensky, PhD, Professor of Biostatistics, Harvard T.H. Chan School of Public Health, & Program Director, Harvard Catalyst Biostatistics Program.
Please visit http://catalyst.harvard.edu/services/biostatsseminar/ for more information about our other courses.
